



Received: October 9, 2025
Revised: November 8, 2025
Accepted: January 27, 2026

Corresponding Author:
Swaathi Ravindran, Department of Oral Pathology and Microbiology, SRM Kattankulathur Dental College and Hospital, Faculty of Medicine and Health Sciences, SRM Institute of Science and Technology, Kattankulathur, Chengalpattu, Tamil Nadu 603203, India
E-mail: swaathir@srmist.edu.in

Oral-Systemic Mechanisms in Diagnostic Medicine: A Syndromic and Translational Review

Kashish Kukreja¹, Arun Kalyan Venkatesh Babu¹, Swaathi Ravindran¹ ,
Magesh Karuppur Thiagarajan¹, Aravindhan Ravi¹

¹Department of Oral Pathology and Microbiology, SRM Kattankulathur Dental College and Hospital, Faculty of Medicine and Health Sciences, SRM Institute of Science and Technology, Kattankulathur, Chengalpattu, Tamil Nadu, India

Abstract

The oral cavity's diagnostic potential remains underutilized in mainstream medicine, despite being a dynamic interface between systemic physiology and environmental exposure. This review proposes a mechanism-based framework that repositions oral structures and secretions as bio-reflective zones, thereby mirroring pathophysiological processes across endocrine, cardiovascular, renal, neurological, and genetic domains. By integrating evidence from salivary biomarkers, mucosal alterations, craniofacial anomalies, and radiographic features, we demonstrate how oral diagnostics can serve as early indicators of systemic dysfunction. Mechanistic clues to multisystem disorders are provided by oral phenotypes, with a particular emphasis on syndromic convergence. The manuscript also underscores the potential for implementation in the fields of interdisciplinary screening protocols, AI-assisted oral imaging, and salivary biosensing. It is imperative to take diagnostic equity into account when examining the potential of oral evaluations to address disparities in underserved populations, particularly in situations where systemic testing is unavailable. By integrating clinical, molecular, and imaging-based insights, this review enhances oral diagnostics from adjunctive observations to actionable tools in the detection and monitoring of systemic diseases, thereby promoting a paradigm.

Keywords: diagnosis, oral cavity, oral manifestations, saliva, systemic diseases

Introduction

The oral cavity has traditionally been viewed as the site of local pathologies such as caries and periodontal disease, yet growing evidence points to its broader role as a diagnostic interface for systemic health. Changes in oral tissues and, more recently, in the molecular composition of saliva, provide valuable insights into physiological disturbances that extend beyond the mouth. Because saliva contains a diverse spectrum of proteins, nucleic acids, metabolites, and microbial signatures, it has emerged as a particularly attractive medium for detecting disease-related alterations in a non-invasive manner.^(1,2)

Despite this potential, the healthcare landscape often remains divided, with dentistry and medicine functioning as largely independent disciplines. Such compartmentalization limits opportunities for early recognition of systemic diseases and diminishes the impact of preventive care. Oral manifestations that might otherwise serve as early diagnostic signals are frequently overlooked or managed in isolation, delaying comprehensive treatment and contributing to higher disease burden.

The review employs a mechanism-based framework to address challenges. Rather than classifying oral manifestations by broad disease categories, the review redefines the oral cavity as a bio-reflective zone, where systemic dysfunctions display through commonly shared biological pathways (allostatic load), such as chronic inflammation, oxidative stress, immune dysregulation, and metabolic deregulation. Through the lens of translational research, the review bridges the connections made in previous reviews by revealing the mechanistic links of oral and saliva findings in a clearly defined structure and emphasising how clinicians can put together the clinically actionable information about systemic health. We highlight translational research—specifically, salivary diagnostics—as a non-invasive diagnostic method that can reveal early indicators of health decline by reviewing more recent clinical, biological, and translational studies.

Oral clues to systemic illness—a mechanism-based framework

Different biological routes enable systemic abnormalities to manifest through the oral cavity's dynamic interface.⁽³⁾ In contrast to disease-based catalogues, a mechanism-oriented approach facilitates the comprehension of the way in which various conditions result in com-

parable oral outcomes.⁽⁴⁾ This method helps clarify the impact of systemic disorders on oral health by examining the dissemination of microbes, inflammatory reactions, immune system changes, and molecular signalling. It provides a comprehensive understanding of the interconnections between oral and systemic health.

The subsequent subsections focus on a specific pathway, illustrating how systemic dysfunction leads to oral and sublingual alterations that have diagnostic potential.

Inflammatory and immune-mediated disorders

Linking systemic disease to oral disease involves fundamental processes such as chronic inflammation and immunological dysregulation. Pro-inflammatory cytokines, altered immune cell profiles, and dysregulated host-microbe interactions form oral symptoms that may precede or follow systemic illness.^(5,6)

- **Diabetes mellitus:** Persistent hyperglycemia promotes low-grade systemic inflammation and impaired neutrophil function, contributing to increased periodontal susceptibility and delayed wound healing.⁽⁷⁾ Elevated salivary levels of advanced glycation end products (AGEs) and inflammatory mediators further reflect disease activity.⁽⁸⁾

- **Rheumatoid arthritis (RA):** Shared pathways of joint and periodontal destruction, including TNF- α and IL-6 signaling, underscore the bidirectional relationship between RA and periodontitis. Oral clinical signs may correlate with systemic disease severity.^(9,10)

- **Systemic lupus erythematosus (SLE):** Immune complex deposition and mucosal vasculitis lead to oral ulcers, lichenoid lesions, and salivary gland dysfunction. Salivary anti-dsDNA antibodies and cytokine profiles have been investigated as non-invasive disease markers.⁽¹¹⁻¹³⁾

- **Inflammatory bowel disease (IBD):** Aberrant mucosal immunity manifests orally as aphthous-like ulcers, mucosal cobble stoning, or pyostomatitis vegetans.^(14,15) Salivary calprotectin and altered microbiome signatures have been proposed as adjunctive diagnostic tools.^(16,17)

Salivary gland dysfunction and secretory imbalance

Alterations in salivary gland structure or function compromise the oral cavity's protective environment, leading to xerostomia, opportunistic infections, and

impaired mucosal healing.⁽¹⁸⁾

- Sjögren's syndrome: Autoimmune destruction of salivary acini reduces flow and alters glandular proteins, producing dryness, rampant caries, and mucosal discomfort. Salivary anti-Ro/SSA antibodies serve as promising non-invasive markers.⁽¹⁹⁻²¹⁾
- HIV infection: Salivary gland disease may manifest as diffuse infiltrative lymphocytosis, parotid swelling, and xerostomia, reflecting immune dysregulation.⁽²²⁾
- Drug-induced xerostomia: Anticholinergics, antihypertensives, and antidepressants can diminish secretion, mimicking glandular disease and complicating oral management.^(23,24)

Recognition of these changes highlights saliva as both a diagnostic fluid and a therapeutic target.

Mucosal and gingival alterations

Systemic hematologic and infectious disorders frequently manifest as mucosal or gingival lesions due to impaired hemostasis, vascular fragility, or viral-mediated inflammation.⁽²⁵⁾

- Leukemia: Gingival hypertrophy, spontaneous bleeding, and petechiae reflect infiltration and thrombocytopenia.^(26,27)
- Thrombocytopenia: Low platelet counts produce ecchymoses and mucosal haemorrhage.⁽²⁸⁾
- COVID-19: Viral tropism for ACE2-expressing oral tissues can result in dysgeusia, mucositis, and ulceration.^(29,30)

These mucosal findings often precede systemic diagnosis, underscoring their clinical value.

Bone metabolism disorders

Oral bone is highly sensitive to systemic disturbances in mineral metabolism, presenting with changes in alveolar bone density and architecture.⁽³¹⁾

- Osteoporosis: Reduced bone mass predisposes to tooth loss and compromised implant stability; salivary calcium and collagen breakdown products have been explored as biomarkers.^(32,33)
- Renal osteodystrophy: Secondary hyperparathyroidism leads to jawbone changes, loss of lamina dura, and brown tumors.^(34,35)

Oral radiography can provide adjunctive insights into skeletal health.

Oral-origin bacteremia and cardiovascular risk

The oral cavity serves as a reservoir for pathogenic bacteria capable of translocating into the bloodstream, contributing to cardiovascular morbidity.⁽³⁶⁾

- Infective endocarditis: Poor oral hygiene and invasive dental procedures can introduce *viridans streptococci* and *Enterococcus* into circulation.^(37,38)
- Periodontitis–cardiac links: Systemic inflammation driven by periodontal pathogens such as *Porphyromonas gingivalis* is implicated in atherogenesis.^(39,40)

Routine periodontal care represents a preventive measure with systemic benefit.

Neurological and sensory manifestations

Neurological disease often alters oral sensation, motor control, and salivary function, reflecting broader neurodegenerative processes.⁽⁴¹⁾

- Parkinson's disease: Impaired motor control leads to drooling and swallowing dysfunction; reduced salivary dopamine metabolites may have biomarker relevance.^(42,43)
 - In Multiple sclerosis, demyelination may result in dysgeusia and trigeminal neuralgia.^(44,45)
 - Zinc deficiency disrupts the function of taste receptors, resulting in hypogeusia or dysgeusia.⁽⁴⁶⁾
- These modifications highlight the diagnostic interaction between neurology and oral medicine.

Gastrointestinal and acid-related damage

Digestive tract disorders frequently present as erosive or pigmentary alterations in oral tissues, showing signs of acid exposure or mucosal pathology.⁽⁴⁷⁾

- Gastroesophageal reflux disease (GERD): prolonged acid exposure erodes enamel and irritates the mucosa.^(48,49)
- Eating disorders: Xerostomia, parotid enlargement, and palatal erosion are caused by episodes of vomiting.⁽⁵⁰⁾
- Before intestinal polyps are found, mucocutaneous pigmentation of the lips and buccal mucosa can serve as a diagnostic hint in Peutz-Jeghers syndrome.⁽⁵¹⁾

Consequently, oral evaluation provides a perspective on gastrointestinal pathology.

Nutrient-linked mucosal and structural alterations

Oral tissues experience rapid nutrient deficiencies as

a result of their high metabolic demands and rapid cellular turnover.

- Iron deficiency causes angular cheilitis and atrophic glossitis; Plummer-Vinson syndrome causes dysphagia and pallor in the oral mucosa.^(52,53)
- B-complex deficiency: Glossitis, cheilitis, and burning mouth are all typical indicators.⁽⁵¹⁾
- Vitamin C deficiency: Leads to gingival bleeding and poor wound healing.⁽⁵⁴⁾
- Vitamin D deficiency: Impairs mineralization, affecting alveolar bone.^(55,56)
- Protein–energy malnutrition: Causes mucosal atrophy and delayed eruption in children.⁽⁵⁷⁾

The oral cavity's susceptibility to systemic nutrition is underscored by these manifestations.

Genetic disorders and syndromic oral features

Early diagnostic markers may be the distinctive oral and craniofacial manifestations of several hereditary and syndromic disorders. The timely genetic assessment and multidisciplinary care can be significantly influenced by a precise oral examination.

- Down syndrome (Trisomy 21): Common oral symptoms include delayed eruption, hypodontia, macroglossia, fissured tongue, and a much higher risk of periodontal disease since the immune system is dysfunctional.⁽⁵⁸⁻⁶⁰⁾
- Major functional and aesthetic implications are associated with ectodermal dysplasia, which is characterised by hypodontia or anodontia, peg-shaped or conical teeth, impaired salivary flow, and xerostomia.⁽⁶¹⁻⁶³⁾
- Cleidocranial dysplasia is characterised by multiple impacted and extra teeth, delayed eruption, and a high-arched mouth. Oral x-rays are often used to help make the diagnosis.^(64,65)
- In Marfan syndrome, defects in the connective tissues cause the jaw joints to be hypermobile, the palate to be high-arched, and crowding to be present.⁽⁶⁶⁾
- Neurofibromatosis type 1: Oral neurofibromas, enlargement of fungiform papillae, and mandibular radiolucencies may be observed.^(67,68)
- Apert syndrome: Midface hypoplasia, high-arched palate, crowding, and delayed eruption result from craniosynostosis and altered jaw development.^(69,70)
- Treacher Collins syndrome: Hypoplastic zygoma and mandible, cleft palate, and dental anomalies such as

enamel hypoplasia are common.^(71,72)

- Turner syndrome: Associated with high-arched palate, micrognathia, and increased risk of malocclusion.^(73,74)
- Williams syndrome: Often presents with small, widely spaced teeth, malocclusion, and increased prevalence of dental caries.⁽⁷⁵⁻⁷⁷⁾
- Osteogenesis imperfecta: Often associated with Dentinogenesis imperfecta in which teeth are translucent, opalescent with rapid wear is a defining oral feature.⁽⁷⁸⁻⁸⁰⁾

Uremic and dialysis associated oral changes

Uremia and dialysis alter the oral environment through metabolic toxins and fluid imbalance.

- Uremic stomatitis, which manifests in advanced renal failure, has an odour similar to ammonia, ulcerations on the mucosal surface, and pseudomembranes.⁽⁸¹⁾
- Dialysis patients often have xerostomia as a result of fluid restriction and the side effects of their medications.^(82,83)
- Changes associated with dialysis: These include petechiae, delayed healing, and an increase in calculus formation.⁽⁸⁴⁻⁸⁶⁾

Clinical and translational implications

Reconceptualising the oral cavity as a bio-reflective zone enables new approaches for the diagnosis, monitoring, and risk stratification of systemic diseases. Early indicators of renal, cardiovascular, neurodegenerative and endocrine diseases can be detected by the changes in the oral cavity, such as craniofacial anomalies, mucosal changes, and salivary biomarkers. As an advantage, the oral evaluations could be incorporated for standard systemic assessment to enhance diagnostic sensitivity and early detection.

Salivary biomarkers: evidence, advantages, and challenges

Saliva is considered a reflection of blood, and its popularity in the field of diagnostics is accelerating, especially as it is a non-invasive and patient-friendly mode of collection.^(87,88) It contains a wide array of biologically relevant constituents like proteins, nucleic acids, antibodies, cytokines, metabolites and microbial components that reveal the immune, inflammatory, endocrine and metabolic states.^(87,89,90) There have been

several correlations that demonstrate the link between serum and salivary biomarkers, such as the inflammatory and cardiac markers, including C-reactive protein and troponins in cardiovascular diseases^(91,92), proteomic signatures and autoantibodies in autoimmune disorders like Sjogren's syndrome^(93,94), salivary glucose levels in diabetes^(95,96), proteomic, microRNA, and spectroscopic signatures in oral and systemic malignancies, including breast, lung and pancreas.⁽⁹⁷⁻¹⁰¹⁾ The salivary biomarkers are also associated with neurodegenerative diseases, including Alzheimer's and Parkinson's.^(102,103) The translational relevance and diagnostic sensitivity are further enhanced using advances in analytical techniques like enzyme-linked immunosorbent assays, quantitative mass spectrometry, Raman spectroscopy and saliva-omics platforms.^(89,104,105) The salivary-based tests offer an upper hand by reducing patient discomfort, being non-invasive and easy to collect, and potentially applicable in large-scale populations.^(106,107) However, the clinical translation remains challenged by biological variability, circadian rhythm, lower biomarker concentrations, salivary flow rate fluctuations, lack of standardised reference ranges and limited large-scale validation across diverse populations. These limitations are to be addressed before relying completely on salivary biomarker-based diagnostics in routine clinical practice.

Artificial intelligence (AI) -assisted oral imaging: clinical relevance, advantages and limitations

Another powerful tool for early detection, monitoring and diagnosis is artificial intelligence (AI) assisted oral imaging. The AI-based algorithms are applied to intraoral photographs, radiographs and cone-beam computed tomography (CBCT), and optical imaging modalities have high sensitivity in identifying dental caries, periapical pathologies, periodontal bone loss, oral potentially malignant disorders and even malignancies like oral squamous cell carcinoma.^(108,109) A lot of things can be carried out using AI-assisted imaging, such as predicting the disease, assessing its severity, and monitoring the progression of the disease, which in turn reduces the inter-observer variability and enhances the diagnostic consistency.^(110,111) This integration of chairside imaging, along with deep learning models, could improve the detection of even subtle oral or radiographic alterations, which could be accidentally missed or over-

looked during routine clinical examination.

AI-assisted oral imaging offers several advantages in a translational perspective, such as rapid analysis of the images, easier when assessing larger patient populations and the possibility of integration into tele-dentistry and remote screening workflows.⁽¹¹²⁾ AI-based imaging systems support a multi-modal diagnostic framework when combined with clinical examination and other diagnostic modalities, which could align the precision and preventive approach.⁽¹¹³⁾ However, there could be several challenges that could be faced, such as varying image quality, lack of standardised imaging protocols, algorithm bias due to non-representative training datasets, data privacy-related concerns, regulatory oversight and the most importantly, widespread clinical adoption of the technique.^(114,115) It is essential to address these limitations through multi-centre validation studies, and standardised reporting guidelines are essential to ensure safe, ethical, and effective integration of AI-assisted oral imaging to routine clinical practice.^(108,114)

Strengths

The clinical value of liquid biopsy has expanded beyond its value for disease assessment.^(116,117) Information at the molecular level will reflect systemic physiological changes at an earlier stage, even before clinical symptoms begin to appear, making salivary biomarker research even more reliable.⁽¹¹⁸⁾ This ability to identify even the slightest biological shift supports earlier clinical risk assessment and long-term monitoring, especially for chronic diseases.^(118,119) Along with the advances in salivary diagnostics integration with AI-assisted analysis of oral images, it helps to identify the changes that could not be detected from visual examination alone, allowing for precise diagnostics.⁽¹²⁰⁾ When considered together, these approaches help to a more integrated understanding of patient health, which is especially relevant for screening and preventive care.

Limitations

Although there are several advantages, these tools face some important challenges that could hinder their application in routine clinical use.⁽¹²¹⁾ The oral conditions and biological variation among individuals influence the salivary biomarkers, which might cause difficulties in interpretation and reduce the specificity. The training data

quality and its diversity play a major role in the performance of AI-assisted imaging, and models developed in controlled environments may not perform consistently across different populations or clinical situations.⁽¹²²⁾ Both approaches also lack widespread longitudinal validation and standardised implementation pathways, making integration into existing clinical workflows uneven. Addressing these limitations will be essential to help oral diagnostic innovations move beyond experimental settings and achieve clinically reliable everyday application.⁽⁸⁹⁾

Future directions

To fully utilise the diagnostic capabilities of the oral cavity, subsequent research should progress from initial discoveries to mechanistic validation and clinical integration. The chairside use with a focus on population-level specificity and sensitivity, which could detect inflammatory, metabolic and neuroendocrine markers using salivary biosensing platforms. AI-assisted oral imaging appears to be promising for early detection of systemic disease when trained on a variety of datasets through pattern identification of disease progression. Syndromic mapping of oral phenotypes should be broadened to encompass underrepresented disorders and populations, thereby facilitating the development of more broad-based diagnostic algorithms. As systemic testing is unavailable in underserved communities, oral diagnostics have the potential to address this. It requires support at the policy level, ethical management of data, and culturally aware implementation. Integrating oral diagnostics into systemic care pathways, refining AI models, and advancing biosensor technology can transform the mouth from a passive site of observation to an active sentinel of whole-body health.

Conclusions

The oral cavity serves as a bio-reflective zone, reflecting systemic health via structural, microbial, and molecular indicators. This review presents oral diagnostics as a mechanism-driven approach for the early detection and monitoring of systemic diseases. Oral features, ranging from salivary biomarkers to craniofacial anomalies, provide insights that extend beyond disciplinary boundaries. To realise this potential, oral diagnostics require validation across diverse populations, integration into screening protocols, and support through interdis-

iplinary collaboration. Recent developments in biosensing, AI-assisted imaging, and syndromic mapping present significant translational opportunities, particularly in underserved areas. We propose a paradigm shift that transforms oral evaluations from supplementary observations into effective instruments for systemic care. Oral diagnostics can integrate clinical silos, fostering an understanding of the mouth not merely as a site of disease, but as an indicator of overall health. Advances in salivary biosensing and AI-assisted oral imaging further support the role of the oral cavity as a scalable, non-invasive diagnostic interface for systemic disease.

Conflict of Interest

The authors declare no conflict of interest.

References

1. Dongiovanni P, Meroni M, Casati S, Goldoni R, Thomaz DV, Kehr NS, *et al.* Salivary biomarkers: novel noninvasive tools to diagnose chronic inflammation. *Int J Oral Sci.* 2023;15(1):27.
2. Surdu A, Foia LG, Luchian I, Trifan D, Tatarciuc MS, Scutariu MM, *et al.* Saliva as a diagnostic tool for systemic diseases-a narrative review. *Medicina (Kaunas).* 2025;61(2):243.
3. Li X, Kolltveit KM, Tronstad L, Olsen I. Systemic diseases caused by oral infection. *Clin Microbiol Rev.* 2000;13(4):547-58.
4. Ahonen H, Pakpour A, Norderyd O, Broström A, Fransson EI, Lindmark U. Applying world dental federation theoretical framework for oral health in a general population. *Int Dent J.* 2022;72(4):536-44.
5. D'Aiuto F, Suvan J, Siripaiboonpong N, Gatzoulis MA, D'Aiuto F. The root of the matter: linking oral health to chronic diseases prevention. *Int J Cardiol Congenit Heart Dis.* 2025;19:100574.
6. Lumelsky N. Oral-systemic immune axis: crosstalk controlling health and disease. *Front Dent Med* 2023;3: doi: 10.3389/fdmed.2022.1106456
7. Zhao M, Xie Y, Gao W, Li C, Ye Q, Li Y. Diabetes mellitus promotes susceptibility to periodontitis—novel insight into the molecular mechanisms. *Front Endocrinol (Lausanne).* 2023;14:1192625.
8. Thomas JT, Joseph B, Varghese S, Kamalasanan Vijayakumari B, Sorsa T, Mauramo M, *et al.* Salivary advanced glycated end products, their receptors, and aMMP-8 in periodontitis patients with varying glycemic levels: a cross-sectional study. *J Periodontol.* 2025;96(8):835-47.
9. de Molon RS, Rossa C Jr, Thurlings RM, Cirelli JA, Koenders MI. Linkage of periodontitis and rheumatoid arthritis: current evidence and potential biological interactions. *Int J*

- Mol Sci. 2019;20(18):4541.
10. Hashimoto H, Hashimoto S, Shimazaki Y. Functional impairment and periodontitis in rheumatoid arthritis. *Int Dent J*. 2022;72(5):641-7.
 11. Zian Z, Bouhoudan A, Mourabit N, Azizi G, Bennani Mechita M. Salivary cytokines as potential diagnostic biomarkers for systemic lupus erythematosus disease. *Mediators Inflamm*. 2021;2021(1):8847557.
 12. Rodsaward P, Prueksrisakul T, Deekajorndech T, Edwards SW, Beresford MW, Chiewchengchol D. Oral ulcers in juvenile-onset systemic lupus erythematosus: a review of the literature. *Am J Clin Dermatol*. 2017;18(6):755-62.
 13. Infantino M, Nagy E, Bizzaro N, Fischer K, Bossuyt X, Damoiseaux J. Anti-dsDNA antibodies in the classification criteria of systemic lupus erythematosus. *J Transl Autoimmun*. 2022;5:100139.
 14. Khozeimeh F, Shakerin H, Daghighzadeh H, Najarzadegan F, Golestannejad Z, Adibi P. Oral manifestations in inflammatory bowel disease: a cross-sectional study in Isfahan. *Dent Res J (Isfahan)*. 2021;18:4.
 15. Atarbashi-Moghadam S, Lotfi A, Atarbashi-Moghadam F. Pyostomatitis vegetans: a clue for diagnosis of silent crohn's disease. *J Clin Diagn Res*. 2016;10(12):ZD12-ZD13.
 16. Nijakowski K, Surdacka A. Salivary Biomarkers for diagnosis of inflammatory bowel diseases: a systematic review. *Int J Mol Sci*. 2020;21(20):7477.
 17. Abdelbary MMH, Hatting M, Bott A, Dahlhausen A, Keller D, Trautwein C, *et al*. The oral-gut axis: salivary and fecal microbiome dysbiosis in patients with inflammatory bowel disease. *Front Cell Infect Microbiol*. 2022;12:1010853.
 18. Al-Janaby H, El-Sakka H, Masood M, Ashani W, Mendis W, M Slack-Smith L, Parsons R, *et al*. Xerostomia and salivary gland hypofunction in patients with oral lichen planus before and after treatment with topical corticosteroids. *Open Dent J*. 2017;11(1):155-63.
 19. Pijpe J, Kalk WW, Bootsma H, Spijkervet FK, Kallenberg CG, Vissink A. Progression of salivary gland dysfunction in patients with Sjögren's syndrome. *Ann Rheum Dis*. 2007;66(1):107-12.
 20. Decup F, Rihab B, Nocturne G, Gosset M. The role of dental professionals in identifying patients with a suspected primary Sjögren's syndrome and suggestions for prevention and treatment of oral complications: a narrative review. *Heliyon*. 2025;11(13):e43564.
 21. Kamounah S, Tayob N, Chiang S, Wei F, Park JK, Kwon HM, *et al*. Immunoassay detects salivary anti-SSA/Ro-52 autoantibodies in seronegative patients with primary Sjögren's syndrome. *Immunohorizons*. 2023;7(7):554-61.
 22. Jeffers L, Webster-Cyriaque JY. Viruses and salivary gland disease (SGD). *Adv Dent Res*. 2011;23(1):79-83.
 23. Ito K, Izumi N, Funayama S, Nohno K, Katsura K, Kaneko N, *et al*. Characteristics of medication-induced xerostomia and effect of treatment. *PLoS One*. 2023;18(1):e0280224.
 24. Daly C. Oral and dental effects of antidepressants. *Aust Prescr*. 2016;39(3):84.
 25. Treviño-Tijerina MC, Garza-Villarreal J, Sáenz-Rangel S, Cruz-Fierro N. Dental dilemmas in blood disorders: navigating oral health in hematological diseases. *Int J Appl Dent Sci*. 2023;9(4):283-9.
 26. Zisis V, Zisis S, Anagnostou E, Dabarakis N, Pouloupoulos A, Andreadis D. Gingival enlargement can constitute the only diagnostic sign of leukemia: report of an unusual case. *Cureus*. 2023;15(10):e47959.
 27. Quispe RA, Aguiar EM, de Oliveira CT, Neves ACX, Santos PSDS. Oral manifestations of leukemia as part of early diagnosis. *Hematol Transfus Cell Ther*. 2022;44(3):392-401.
 28. Khammissa RAG, Fourie J, Masilana A, Lawrence S, Lemmer J, Feller L. Oral manifestations of thrombocytopaenia. *Saudi Dent J*. 2018;30(1):19-25.
 29. Hans M, Hans VM, Kahlon N, Sagar M, Pandey AK, Das A. Gustatory dysfunction and oral ulceration in COVID-19 patients: a cross sectional study. *Dent Res J (Isfahan)*. 2022;19:43.
 30. Iranmanesh B, Khalili M, Amiri R, Zartab H, Aflatoonian M. Oral manifestations of COVID-19 disease: a review article. *Dermatol Ther*. 2021;34(1):e14578.
 31. Zhu L, Zhou C, Chen S, Huang D, Jiang Y, Lan Y, *et al*. Osteoporosis and alveolar bone health in periodontitis niche: a predisposing factors-centered review. *Cells*. 2022;11(21):3380.
 32. Ng PYB, Donley M, Hausmann E, Hutson AD, Rossomando EF, Scannapieco FA. Candidate salivary biomarkers associated with alveolar bone loss: cross-sectional and *in vitro* studies. *FEMS Immunol Med Microbiol*. 2007;49(2):252-60.
 33. Karunakaran N, Maiti S, Jayaraman S, Paulraj J. Assessment of bone turnover markers prior to dental implant placement for osteoporosis patient- a case- control study. *Ann Dent Spec*. 2023;11(2):57-61.
 34. J P, Nisha V A, Gs A, Ca P, Mm V. Oral manifestations in a renal osteodystrophy patient - a case report with review of literature. *J Clin Diagn Res*. 2014;8(8):ZD28-30.
 35. Dagistan S, Miloglu O, Caglayan F. Changes in jawbones of male patients with chronic renal failure on digital panoramic radiographs. *Eur J Dent*. 2016;10(1):64-8.
 36. Gendron R, Grenier D, Maheu-Robert LF. The oral cavity as a reservoir of bacterial pathogens for focal infections. *Microbes Infect*. 2000;2(8):897-906.
 37. Bumm C V, Folwaczny M. Infective endocarditis and oral health-a narrative review. *Cardiovasc Diagn Ther*. 2021;11(6):1403-15.
 38. Del Giudice C, Vaia E, Liccardo D, Marzano F, Valletta A, Spagnuolo G, *et al*. Infective endocarditis: a focus on oral microbiota. *Microorganisms*. 2021;9(6):1218.
 39. Leishman SJ, Do HL, Ford PJ. Cardiovascular disease

- and the role of oral bacteria. *J Oral Microbiol.* 2010;2: doi: 10.3402/jom.v2i0.5781.
40. Peng X, Cheng L, You Y, Tang C, Ren B, Li Y, *et al.* Oral microbiota in human systematic diseases. *Int J Oral Sci.* 2022;14(1):14.
 41. Wu Y, Lan Y, Mao J, Shen J, Kang T, Xie Z. The interaction between the nervous system and the stomatognathic system: from development to diseases. *Int J Oral Sci.* 2023;15(1):34.
 42. Srivannichapoom P, Pandey S, Hallett M. Drooling in Parkinson's disease: a review. *Parkinsonism Relat Disord.* 2014;20(11):1109-18.
 43. De Bartolo MI, Belvisi D, Mancinelli R, Costanzo M, Caturano C, Leodori G, *et al.* A systematic review of salivary biomarkers in Parkinson's disease. *Neural Regen Res.* 2024;19(12):2613-25.
 44. Chemaly D, Lefrançois A, Pérusse R. Oral and maxillofacial manifestations of multiple sclerosis. *J Can Dent Assoc.* 2000;66(11):600-5.
 45. Al Johani K, Fudah M, Al-Zahrani M, Abed H, Srivastava KC, Shrivastava D, *et al.* Multiple sclerosis—a demyelinating disorder and its dental considerations—a literature review with own case report. *Brain Sci.* 2023;13(7):1009.
 46. Gooding AJ, Packer CD, Pensiero AL. Zinc Deficiency-induced hypogeusia in a patient with refractory iron-deficiency anemia: a case report. *Cureus.* 2019;11(12):e6365.
 47. Ansari A, Anwarhussain Mulla S, Patil A, Bedia AS, More S, Jaiswal H, *et al.* Oral manifestations associated with gastrointestinal diseases-a review. *Bioinformation.* 2025;21(3):383-9.
 48. Cengiz S, Cengiz MI, Saraç YS. Dental erosion caused by gastroesophageal reflux disease: a case report. *Cases J.* 2009;2:8018.
 49. Păduraru G, Ghiga G, Gimiga N, Lupu VV, Bozomitu L, Adam Răileanu A, *et al.* oral manifestations of anorexia in adolescent patients. *Rom J Oral Rehabil.* 2024;16(1):686-92.
 50. Kothiwale S. An oral clinician's perspective towards Peutz Jegher's syndrome-a case Report. *J Prob Health.* 2015;3(1):1-2.
 51. Lešić S, Ivanišević Z, Špiljak B, Tomas M, Šoštarić M, Včev A. The impact of vitamin deficiencies on oral manifestations in children. *Dent J (Basel).* 2024;12(4):109.
 52. Samad A, Mohan N, Balaji RVS, Augustine D, Patil SG. Oral manifestations of plummer-vinson syndrome: a classic report with literature review. *J Int Oral Health.* 2015;7(3): 68-71.
 53. Vanam C, Thammisetty DP. Case report on plummer vinson syndrome. *Int J Basic Clin Pharmacol.* 2019;8(10):2334.
 54. Chaluvarej R, Ashley PF, Parekh S. Scurvy presenting primarily as gingival manifestation in a young child: a diagnostic dilemma. *BMJ Case Rep.* 2022;15(6):e249113.
 55. Botelho J, Machado V, Proença L, Delgado AS, Mendes JJ. Vitamin D deficiency and oral health: a comprehensive review. *Nutrients.* 2020;12(5):1471.
 56. Jagelavičienė E, Vaitkevičienė I, Šilingaitė D, Šinkūnaitė E, Daugėlaitė G. The relationship between vitamin D and periodontal pathology. *Medicina (Kaunas).* 2018; 54(3):45.
 57. Sheetal A, Hiremath VK, Patil AG, Sajjansetty S, Kumar SR. Malnutrition and its oral outcome - a review. *J Clin Diagn Res.* 2013;7(1):178-80.
 58. Al-Maweri SA, Tarakji B, Al-Sufyani GA, Al-Shamiri HM, Gazal G. Lip and oral lesions in children with down syndrome. A controlled study. *J Clin Exp Dent.* 2015;7(2):e284-8.
 59. Goud EVSS, Gulati S, Agrawal A, Pani P, Nishant K, Pattnaik SJ, *et al.* Implications of Down's syndrome on oral health status in patients: a prevalence-based study. *J Family Med Prim Care.* 2021;10(11):4247-52.
 60. Nirmala S. Dental concerns of children with down's syndrome-an overview. *J Pediatr Neonatal Care.* 2017; 6(3):248.
 61. Bergendal B. Orofacial manifestations in ectodermal dysplasia-a review. *Am J Med Genet A.* 2014;164A(10): 2465-71.
 62. Morandini AC, Adeogun O, Black M, Holman E, Collins K, James W, *et al.* Ectodermal dysplasia: a narrative review of the clinical and biological aspects relevant to oral health. *Front Pediatr.* 2025;13:1523313.
 63. Elgasmi FE, Rahmaoui M, Elarabi S, Badre B. Dental management of ectodermal dysplasia: a report of two clinical cases. *Cureus.* 2025;17(5):e84031.
 64. Pan CY, Tseng YC, Lan TH, Chang HP. Craniofacial features of cleidocranial dysplasia. *J Dent Sci.* 2017;12(4):313-8.
 65. Roberts T, Stephen L, Beighton P. Cleidocranial dysplasia: a review of the dental, historical, and practical implications with an overview of the South African experience. *Oral Surg Oral Med Oral Pathol Oral Radiol.* 2013;115(1):46-55.
 66. Bostanci B, Korkut E, Unlu N. Dental findings in marfan syndrome: a case report. *J Istanbul Univ Fac Dent.* 2017;51(2):61-7.
 67. Wotjiuk F, Hyon I, Dajean-Trutaud S, Badran Z, Prud'homme T. Dental management of neurofibromatosis type 1: a case report and literature review. *Int J Clin Pediatr Dent.* 2019;12(6):577-81.
 68. Javed F, Ramalingam S, Ahmed HB, Gupta B, Sundar C, Qadri T, *et al.* Oral manifestations in patients with neurofibromatosis type-1: a comprehensive literature review. *Crit Rev Oncol Hematol.* 2014;91(2):123-9.
 69. Droubi L, Laflouf M, Tolibah YA, Comisi JC. Apert syndrome: dental management considerations and objectives. *J Oral Biol Craniofac Res.* 2022;12(3):370-5.
 70. Vadiati Saberi B, Shakoorpour A. Apert syndrome: report of a case with emphasis on oral manifestations. *J Dent (Tehran).* 2011;8(2):90-5.
 71. Martelli-Junior H, Coletta RD, Miranda RT, Barros LM de, Swerts MS, Bonan PR. Orofacial features of Treacher Collins syndrome. *Med Oral Patol Oral Cir Bucal.* 2009;

- 14(7):E344-8.
72. Chang CC, Steinbacher DM. Treacher Collins syndrome. *Semin Plast Surg.* 2012;26(2):83-90.
73. Ahiko N, Baba Y, Tsuji M, Horikawa R, Moriyama K. Investigation of maxillofacial morphology and oral characteristics with Turner syndrome and early mixed dentition. *Congenit Anom (Kyoto).* 2019;59(1):11-7.
74. Szilágyi A, Keszthelyi G, Nagy G, Madléna M. Oral manifestations of patients with Turner syndrome. *Oral Surg Oral Med Oral Pathol Oral Radiol Endod.* 2000;89(5):577-84.
75. Poornima P, Patil PS, Subbareddy V V, Arora G. Dentofacial characteristics in William's syndrome. *Contemp Clin Dent.* 2012;3(Suppl 1):S41-4.
76. Wong D, Ramachandra SS, Singh AK. Dental management of patient with Williams syndrome - a case report. *Contemp Clin Dent.* 2015;6(3):418-20.
77. Vavetsi K, Panagopoulou O, Koromantzios P, Fryssira H, Bobetsis SA, Emmanouil D, *et al.* Oral manifestations of nine individuals with Williams syndrome. a case series. *Spec Care Dentist.* 2024;44(2):438-49.
78. Teixeira CS, Felipe MCS, Felipe WT, Silva-Sousa YTC, Sousa-Neto MD. The role of dentists in diagnosing osteogenesis imperfecta in patients with dentinogenesis imperfecta. *J Am Dent Assoc.* 2008;139(7):906-14.
79. Biria M, Abbas FM, Mozaffar S, Ahmadi R. Dentinogenesis imperfecta associated with osteogenesis imperfecta. *Dent Res J (Isfahan).* 2012;9(4):489-94.
80. Ventura L, Verdonk SJE, Zhytnik L, Ridwan-Pramana A, Gilijamse M, Schreuder WH, *et al.* Dental abnormalities in osteogenesis imperfecta: a systematic review. *Calcif Tissue Int.* 2024;115(5):461-79.
81. Gupta M, Gupta M, Abhishek. Oral conditions in renal disorders and treatment considerations-a review for pediatric dentist. *Saudi Dent J.* 2015;27(3):113-9.
82. Deepika ADN, Sridevi K, Buduru K, Malempati S, Ramya K, Sahi BK. Oral manifestations of chronic renal failure patients on hemodialysis. *Uttar Pradesh J Zool.* 2023;44(20):12-9.
83. Oyetola EO, Owotade FJ, Agbelusi GA, Fatusi OA, Sanusi AA. Oral findings in chronic kidney disease: implications for management in developing countries. *BMC Oral Health.* 2015;15:24.
84. García-Rios P, Rodríguez-Lozano FJ, Pérez-Guzmán N. Oral findings linked to chronic kidney disease: a comprehensive systematic review. *J Clin Med.* 2025;14(12):4380.
85. Dembowska E, Jaroń A, Gabrysz-Trybek E, Bładowska J, Trybek G. Oral mucosa status in patients with end-stage chronic kidney disease undergoing hemodialysis. *Int J Environ Res Public Health.* 2023;20(1):835.
86. Kaushik A, Reddy SS, Umesh L, Devi BK, Santana N, Rakesh N. Oral and salivary changes among renal patients undergoing hemodialysis: a cross-sectional study. *Indian J Nephrol.* 2013;23(2):125-9.
87. Wong DT. Salivary diagnostics powered by nanotechnologies, proteomics and genomics. *J Am Dent Assoc.* 2006;137(3):313-21.
88. Ding C, Ji X, Chen X, Xu Y, Zhong L. TNF- α gene promoter polymorphisms contribute to periodontitis susceptibility: evidence from 46 studies. *J Clin Periodontol.* 2014;41(8):748-59.
89. Albagieh H, Alshehri AZ, Alduraywishi AS, Aldaws A, AlBalawi SS, Abu Shaqqaf HF, *et al.* Evaluation of salivary diagnostics: applications, benefits, challenges, and future prospects in dental and systemic disease detection. *Cureus.* 2025;17(1):e77520.
90. Meleti M, Cassi D, Vescovi P, Setti G, Pertinhez TA, Pezzi ME. Salivary biomarkers for diagnosis of systemic diseases and malignant tumors. a systematic review. *Med Oral Patol Oral Cir Bucal.* 2020;25(2):e299-e310.
91. Mirzaii-Dizgah I, Riahi E. Salivary high-sensitivity cardiac troponin T levels in patients with acute myocardial infarction. *Oral Dis.* 2013;19(2):180-4.
92. Floriano PN, Christodoulides N, Miller CS, Ebersole JL, Spertus J, Rose BG, *et al.* Use of saliva-based nano-biochip tests for acute myocardial infarction at the point of care: a feasibility study. *Clin Chem.* 2009;55(8):1530-8.
93. Giusti L, Baldini C, Ciregia F, Giannaccini G, Giacomelli C, De Feo F, *et al.* Is GRP78/BiP a potential salivary biomarker in patients with rheumatoid arthritis?. *Proteomics Clin Appl.* 2010;4(3):315-24.
94. Hu S, Wang J, Meijer J, Jeong S, Xie Y, Yu T, *et al.* Salivary proteomic and genomic biomarkers for primary Sjögren's syndrome. *Arthritis Rheum.* 2007;56(11):3588-600.
95. Rao P V, Reddy AP, Lu X, Dasari S, Krishnaprasad A, Biggs E, *et al.* Proteomic identification of salivary biomarkers of type-2 diabetes. *J Proteome Res.* 2009;8(1):239-45.
96. Vered M, Peleg O, Taicher S, Buchner A. The immunoprofile of odontogenic keratocyst (keratocystic odontogenic tumor) that includes expression of PTCH, SMO, GLI-1 and bcl-2 is similar to ameloblastoma but different from odontogenic cysts. *J Oral Pathol Med.* 2009;38(7):597-604.
97. Zhang L, Farrell JJ, Zhou H, Elashoff D, Akin D, Park N, *et al.* Salivary transcriptomic biomarkers for detection of resectable pancreatic cancer. *Gastroenterology.* 2010;138(3):949-57.
98. Ahmed M, Carrascosa LG, Wuethrich A, Mainwaring P, Trau M. An exosomal- and interfacial-biosensing based strategy for remote monitoring of aberrantly phosphorylated proteins in lung cancer cells. *Biomater Sci.* 2018;6(9):2336-41.
99. Xie Z, Yin X, Gong B, Nie W, Wu B, Zhang X, *et al.* Salivary microRNAs show potential as a noninvasive biomarker for detecting resectable pancreatic cancer. *Cancer Prev Res (Phila).* 2015;8(2):165-73.
100. Koizumi T, Shetty V, Yamaguchi M. Salivary cytokine panel indicative of non-small cell lung cancer. *J Int Med Res.* 2018;46(9):3570-82.

101. Freitas AJA de, Causin RL, Varuzza MB, Calfa S, Hidalgo Filho CMT, Komoto TT, *et al.* Liquid biopsy as a tool for the diagnosis, treatment, and monitoring of breast cancer. *Int J Mol Sci.* 2022;23(17):9952.
102. Chen Y, Zheng J, Su L, Chen F, Zhu R, Chen X, *et al.* Increased salivary microRNAs that regulate DJ-1 gene expression as potential markers for Parkinson's disease. *Front Aging Neurosci.* 2020;12:210.
103. Hisamatsu D, Masuoka H, Takeshige-Amano H, Kurokawa R, Ogata Y, Suda W, *et al.* Acetylcholinesterase inhibitors considerably affect the salivary microbiome in patients with Alzheimer's disease. *iScience.* 2025;28(6):112593.
104. Spielmann N, Wong D. Saliva: diagnostics and therapeutic perspectives. *Oral Dis.* 2011;17(4):345-54.
105. Zhang L, Xiao H, Wong DT. Salivary biomarkers for clinical applications. *Mol Diagn Ther.* 2009;13(4):245-59.
106. Javaid MA, Ahmed AS, Durand R, Tran SD. Saliva as a diagnostic tool for oral and systemic diseases. *J Oral Biol Craniofac Res.* 2016;6(1):67-76.
107. Senf B, Yeo WH, Kim JH. Recent advances in portable biosensors for biomarker detection in body fluids. *Biosensors (Basel).* 2020;10(9):127.
108. Kazimierczak N, Sultani N, Chwarścianek N, Krzykowski S, Janiszewska-Olszowska J, Serafin Z, *et al.* Detection accuracy of an AI platform for dental treatment features on panoramic radiographs-tooth and patient-level analyses. *Sci Rep.* 2025;16(1):2436.
109. Zhang YL, Zhang XK, Fu TG. Artificial intelligence reshapes early oral cancer screening: from image recognition to risk prediction. *Int J Surg.* 2025;111(12):9874-5.
110. Mahesh Batra A, Reche A. A new era of dental care: harnessing artificial intelligence for better diagnosis and treatment. *Cureus.* 2023;15(11):e49319.
111. Al-Khalifa KS, Ahmed WM, Azhari AA, Qaw M, Alsheikh R, Alqudaihi F, *et al.* The use of artificial intelligence in caries detection: a review. *Bioengineering (Basel).* 2024;11(9):936.
112. Kaushik R, Rapaka R. AI-driven evolution in teledentistry: a comprehensive overview of technology and clinical applications. *Dent Rev.* 2025;5(2):100154.
113. Inchingolo AD, Marinelli G, Fiore A, Balestriere L, Carone C, Inchingolo F, *et al.* Diagnostic support in dentistry through artificial intelligence: a systematic review. *Bioengineering (Basel).* 2025;12(11):1244.
114. Farooqi OA. Independent validation of dental AI: a local imperative for trust and safety. *Int Dent J.* 2026;76(1):104029.
115. Koçak B, Ponsiglione A, Stanzione A, Bluethgen C, Santinha J, Ugga L, *et al.* Bias in artificial intelligence for medical imaging: fundamentals, detection, avoidance, mitigation, challenges, ethics, and prospects. *Diagn Interv Radiol.* 2025;31(2):75-88.
116. Limaye S, Shreenivas A, Patil D, Sambath J, George IA, Parab A, *et al.* Liquid biopsy- a pivotal test to help navigate clinical decisions at a precision center in India!. *J Liq Biopsy.* 2025;9:100323.
117. Caputo V, Ciardiello F, Della Corte CM, Martini G, Troiani T, Napolitano S. Diagnostic value of liquid biopsy in the era of precision medicine: 10 years of clinical evidence in cancer. *Explor Target Antitumor Ther.* 2023;4(1):102-38.
118. Starska-Kowarska K. Salivaomic biomarkers—an innovative approach to the diagnosis, treatment, and prognosis of oral cancer. *Biology (Basel).* 2025;14(7):852.
119. Connal S, Cameron JM, Sala A, Brennan PM, Palmer DS, Palmer JD, *et al.* Liquid biopsies: the future of cancer early detection. *J Transl Med.* 2023;21(1):118.
120. Adeoye J, Su Y. Artificial intelligence in salivary biomarker discovery and validation for oral diseases. *Oral Dis.* 2024;30(1):23-37.
121. Li Y, Ou Y, Fan K, Liu G. Salivary diagnostics: opportunities and challenges. *Theranostics.* 2024;14(18):6969-90.
122. Patil S, Albogami S, Hosmani J, Mujoo S, Kamil MA, Mansour MA, *et al.* Artificial intelligence in the diagnosis of oral diseases: applications and pitfalls. *Diagnostics (Basel).* 2022;12(5):1029.